VIDAZA® (Azacitidine) July 25, 2022July 25, 2022 RR FDA Approvals Myeloproliferative Disorders The FDA on May 20, 2022, approved VIDAZA® for pediatric patients with newly diagnosed Juvenile MyeloMonocytic Leukemia (JMML). VIDAZA® is a product of Celgene Corp. Related Posts:VIDAZA® plus VENCLEXTA® for Elderly patients…ONUREG® (Azacitidine tablets)DACOGEN® May Be Superior to VIDAZA® in…Long Term Overall Survival Benefit with VIDAZA®…Long Term Overall Survival Benefit with VIDAZA®…Acute Myeloid Leukemia: Who Is an Appropriate…
